Tumor Mutations Often Unidentified, Limiting Use of Advanced Targeted Therapies

Advanced targeted therapies for cancer are frequently not utilized due to the failure to identify specific mutations in tumors. STAT News reported that this occurs because molecular testing is not routinely performed or completed in a timely manner. As a result, patients may miss opportunities for treatments matched to their tumor's genetic profile.

Targeted therapies work by attacking specific genetic alterations in cancer cells, differing from traditional chemotherapy that affects both healthy and cancerous cells. According to the report, only a portion of eligible patients receive these therapies because of identification barriers.

This affects various cancer types, including lung, breast, and colorectal cancers, where mutations like EGFR or KRAS are common targets.

Several factors contribute to the underuse of these therapies.

Limited access to comprehensive genomic testing in some healthcare settings prevents mutation detection. STAT News noted that even when testing is available, results can take weeks, delaying treatment decisions. Insurance coverage and cost also play roles, as not all payers reimburse for broad-panel testing required to find actionable mutations.

The report indicated that in the United States, approximately 30 percent of advanced cancer patients do not undergo any molecular testing before starting treatment. This statistic underscores the gap between available technologies and clinical practice.

with unidentified mutations often receive less effective standard treatments, potentially leading to poorer outcomes.

Oncologists rely on testing to select therapies like tyrosine kinase inhibitors for specific mutations. Without it, treatment selection defaults to broader approaches. The stakes involve not only individual patient survival rates but also broader healthcare efficiency.